|
EEUBRIGHT Medical Technology Co., Ltd. (688050.SS) Évaluation DCF
CN | Healthcare | Medical - Instruments & Supplies | SHH
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS) Bundle
Rationalisez votre analyse et améliorez la précision avec notre calculatrice DCF (688050SS)! Équipées de données réelles de Eyebright Medical Technology (Beijing) Co., Ltd. et des hypothèses personnalisables, cet outil vous permet de prévoir, d'analyser et d'évaluer les yeux comme un investisseur expert.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195.2 | 273.0 | 433.1 | 579.5 | 951.2 | 1,418.3 | 2,114.8 | 3,153.4 | 4,702.0 | 7,011.2 |
| Revenue Growth, % | 0 | 39.88 | 58.61 | 33.81 | 64.14 | 49.11 | 49.11 | 49.11 | 49.11 | 49.11 |
| EBITDA | 94.0 | 137.7 | 228.2 | 318.5 | 423.9 | 711.5 | 1,060.9 | 1,581.9 | 2,358.8 | 3,517.2 |
| EBITDA, % | 48.18 | 50.43 | 52.69 | 54.96 | 44.56 | 50.17 | 50.17 | 50.17 | 50.17 | 50.17 |
| Depreciation | 24.2 | 30.3 | 39.4 | 52.4 | 86.5 | 143.8 | 214.4 | 319.7 | 476.7 | 710.8 |
| Depreciation, % | 12.38 | 11.08 | 9.09 | 9.05 | 9.09 | 10.14 | 10.14 | 10.14 | 10.14 | 10.14 |
| EBIT | 69.9 | 107.4 | 188.8 | 266.1 | 337.4 | 567.7 | 846.5 | 1,262.2 | 1,882.1 | 2,806.4 |
| EBIT, % | 35.8 | 39.35 | 43.6 | 45.92 | 35.47 | 40.03 | 40.03 | 40.03 | 40.03 | 40.03 |
| Total Cash | 196.3 | 537.1 | 473.4 | 836.9 | 556.8 | 1,300.7 | 1,939.4 | 2,891.9 | 4,312.1 | 6,429.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 58.3 | 82.4 | 85.1 | 103.5 | 212.8 | 340.2 | 507.3 | 756.4 | 1,127.9 | 1,681.8 |
| Account Receivables, % | 29.87 | 30.17 | 19.66 | 17.86 | 22.37 | 23.99 | 23.99 | 23.99 | 23.99 | 23.99 |
| Inventories | 60.8 | 59.1 | 56.0 | 78.8 | 181.4 | 279.0 | 416.1 | 620.4 | 925.1 | 1,379.4 |
| Inventories, % | 31.14 | 21.63 | 12.94 | 13.6 | 19.07 | 19.67 | 19.67 | 19.67 | 19.67 | 19.67 |
| Accounts Payable | .3 | 2.2 | 5.6 | 13.9 | 49.0 | 27.7 | 41.4 | 61.7 | 91.9 | 137.1 |
| Accounts Payable, % | 0.14389 | 0.7981 | 1.29 | 2.39 | 5.16 | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 |
| Capital Expenditure | -141.6 | -118.7 | -311.2 | -271.0 | -370.3 | -776.1 | -1,157.2 | -1,725.5 | -2,572.9 | -3,836.5 |
| Capital Expenditure, % | -72.55 | -43.48 | -71.86 | -46.77 | -38.94 | -54.72 | -54.72 | -54.72 | -54.72 | -54.72 |
| Tax Rate, % | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 |
| EBITAT | 66.9 | 93.4 | 172.3 | 234.5 | 313.0 | 516.4 | 770.0 | 1,148.2 | 1,712.1 | 2,552.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -169.3 | -15.5 | -95.9 | -17.0 | -147.5 | -362.3 | -463.3 | -690.8 | -1,030.1 | -1,535.9 |
| WACC, % | 6.79 | 6.77 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3,211.7 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -1,597 | |||||||||
| Terminal Value | -57,454 | |||||||||
| Present Terminal Value | -41,387 | |||||||||
| Enterprise Value | -44,599 | |||||||||
| Net Debt | -147 | |||||||||
| Equity Value | -44,452 | |||||||||
| Diluted Shares Outstanding, MM | 105 | |||||||||
| Equity Value Per Share | -422.35 |
Benefits You Will Receive
- Customizable Forecast Assumptions: Effortlessly adjust parameters (growth %, margins, WACC) to explore various scenarios.
- Real-Time Financial Data: Eyebright Medical Technology’s (688050SS) financial figures pre-loaded to facilitate your analysis.
- Automated DCF Calculations: The template computes Net Present Value (NPV) and intrinsic value for you effortlessly.
- Professional and Adaptable: A refined Excel model tailored to meet your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and optimizing your time.
Key Features
- Real-World EYEBRIGHT Data: Pre-loaded with Eyebright Medical Technology's historical performance and future projections.
- Completely Customizable Inputs: Tailor parameters like revenue growth, profit margins, discount rates, tax implications, and capital investments.
- Adaptive Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your customized data.
- Scenario Analysis: Develop multiple forecasting scenarios to evaluate various valuation possibilities.
- User-Centric Design: Intuitive and organized, catering to both experienced professionals and newcomers.
How It Functions
- 1. Access the Template: Download and open the Excel file featuring Eyebright Medical Technology's (688050SS) preloaded data.
- 2. Adjust Assumptions: Modify essential inputs such as growth rates, WACC, and capital expenditures.
- 3. Instant Result Viewing: The DCF model automatically calculates intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Evaluate multiple forecasts to investigate various valuation outcomes.
- 5. Present with Assurance: Showcase professional valuation insights to guide your decision-making.
Why Opt for Eyebright Medical Technology's Tool?
- User-Friendly Design: Tailored for both novices and experienced users.
- Customizable Parameters: Seamlessly adjust inputs to suit your specific analysis needs.
- Real-Time Adjustments: Watch Eyebright Medical's valuation change instantly as you modify inputs.
- Preloaded Data: Comes equipped with Eyebright Medical's actual financial data for swift evaluations.
- Preferred Choice Among Experts: Widely utilized by investors and analysts for informed decision-making.
Who Can Benefit from Eyebright Medical Technology (Beijing) Co., Ltd. (688050SS)?
- Investors: Make informed investment choices with our advanced medical technology insights.
- Healthcare Analysts: Streamline your research with comprehensive data and analytics tailored for the industry.
- Consultants: Easily modify our resources for impactful client presentations and reports.
- Medical Professionals: Enhance your knowledge of cutting-edge technologies through practical examples and applications.
- Educators and Students: Utilize our resources as a hands-on learning tool in medical technology and healthcare courses.
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Eyebright Medical Technology (Beijing) Co., Ltd. (688050SS), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A specific sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models displaying intrinsic value along with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) available for thorough analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios specific to Eyebright Medical Technology (Beijing) Co., Ltd. (688050SS).
- Dashboard and Charts: Visual representation of valuation results and assumptions for easy analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.